Antithrombotics in thrombosis and cancer

Area of Science:

• Oncology
• Hematology
• Biochemistry

Background:

• Cancer patients often experience hypercoagulability and thrombosis due to cancer and its treatments.
• Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) impact tumor growth and metastasis.
• Warfarin also affects survival in cancer patients with thromboembolic disorders.

Purpose of the Study:

• To investigate the role of anticoagulants in cancer-associated thrombosis.
• To explore the mechanisms by which heparin and warfarin affect tumor growth and metastasis.
• To evaluate the therapeutic potential of modulating coagulation pathways in cancer treatment.

Main Methods:

• Review of clinical trials and laboratory studies on heparin and warfarin in cancer patients.
• Analysis of the effects of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) on coagulation and tumor processes.
• Investigation of the impact of warfarin, anti-VIIa, and tissue factor pathway inhibitor (TFPI) on angiogenesis, tumor growth, and metastasis.

Main Results:

• LMWH and warfarin demonstrate a clinically relevant effect on the survival of cancer patients with deep vein thrombosis and thromboembolic disorders.
• Heparin and warfarin interfere with fibrin formation, growth factor binding, and matrix-degrading enzymes.
• Laboratory studies show LMWH, warfarin, anti-VIIa, and TFPI play significant roles in regulating angiogenesis, tumor growth, and metastasis.

Conclusions:

• Modulation of tissue factor/VIIa noncoagulant activities by LMWH, warfarin, anti-VIIa, or TFPI may inhibit angiogenesis.
• These anticoagulants represent a potential therapeutic strategy for inhibiting angiogenesis in human tumor growth and metastasis.
• Targeting coagulation pathways offers a promising avenue for improving outcomes in cancer patients with thrombosis.